All the news Showing 10 of 27 articles from: Treatment in cirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Nivolumab improves outcomes in liver cancer study Liz Highleyman / 13 November 2017 Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumour size or disease stabilisation in people with hepatocellular carcinoma (HCC) in the CheckMate ... Maviret cures most people with HCV genotype 3 and those with cirrhosis Liz Highleyman / 24 October 2017 Glecaprevir and pibrentasvir, the two drugs in the recently approved Maviret co-formulation, demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver ... Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK AbbVie press release / 10 May 2017 Albumin reduces complications and improves survival in people with decompensated cirrhosis Liz Highleyman / 08 May 2017 Long-term administration of human albumin was associated with fewer serious complications, less hospitalisation, better quality of life and longer survival for people with decompensated liver cirrhosis, according to a report at the International ... New AbbVie hepatitis C combination cures 99% of people with cirrhosis Keith Alcorn / 21 April 2017 A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side-effects, ... Antibiotic prophylaxis reduces the risk of short-term death in people with decompensated cirrhosis Keith Alcorn / 20 April 2017 Long-term prophylaxis with the antibiotic norfloxacin significantly reduced the incidence of deaths in people with decompensated cirrhosis over a six-month follow-up period, a French randomised trial reported today at the International Liver Congress ... Portal hypertension less likely to fall after HCV treatment when liver stiffness is severe Keith Alcorn / 24 November 2016 Curing hepatitis C infection moderately reduces portal hypertension, but has less impact in people with more severe liver stiffness due to fibrosis, Spanish researchers reported at the 2016 AASLD Liver Meeting last week ... EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... Only treating patients with cirrhosis with DAAs will have limited impact on HCV epidemic in England Michael Carter / 24 May 2016 Targeting new hepatitis C virus (HCV) direct-acting antivirals (DAAs) at patients with cirrhosis will substantially reduce short-term incidence of end-stage liver disease (ESLD) and liver cancer (HCC) in England, according to a model ... Next-generation HCV treatments should benefit challenging patient groups Digestive Disease Week blog / 23 May 2016 ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive